Comparative Pharmacology
Head-to-head clinical analysis: HUMIRA versus HYRIMOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMIRA versus HYRIMOZ.
HUMIRA vs HYRIMOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor alpha (TNF-α) inhibitor; a recombinant human IgG1 monoclonal antibody that binds to soluble and membrane-bound TNF-α, preventing its interaction with p55 and p75 TNF receptors, thereby reducing inflammation and immune activation.
HYRIMOZ (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, thereby reducing inflammation and immune responses mediated by TNF.
Adult: 40 mg subcutaneously every other week. For ulcerative colitis: initial dose 160 mg on day 1, then 80 mg on day 15, then 40 mg every other week starting day 29.
Subcutaneous injection: 40 mg every other week, or 80 mg every other week in patients with inadequate response. For induction in ulcerative colitis: 160 mg on day 1, 80 mg on day 15, then 40 mg every other week.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 10–20 days) in adults, supporting a subcutaneous dosing interval of every 2 weeks. Longer half-life in older patients.
11-17 days (mean ~14 days). The long half-life supports subcutaneous every-other-week dosing with potential dose interval adjustment in patients with high body weight or if trough levels are subtherapeutic.
Adalimumab is primarily eliminated via reticuloendothelial system degradation; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Predominantly catabolized to amino acids; renal excretion of metabolites and unchanged drug is negligible (<1%). Biliary/fecal excretion of intact antibody is minimal (<0.1%).
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor